Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

1.

Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.

Ohki T, Yokoi H, Kichikawa K, Kimura T, Snyder SA, Ragheb AO, O'Leary EE, Jaff MR, Ansel GM, Dake MD.

J Endovasc Ther. 2014 Oct;21(5):644-53. doi: 10.1583/14-4753.1.

PMID:
25290792
2.

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.

Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM; VIBRANT Investigators.

J Vasc Surg. 2013 Aug;58(2):386-95.e4. doi: 10.1016/j.jvs.2013.01.050. Epub 2013 May 13.

PMID:
23676191
3.

Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.

Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Snyder SA, O'Leary EE, Tepe G, Scheinert D, Zeller T; Zilver PTX Investigators.

J Am Coll Cardiol. 2013 Jun 18;61(24):2417-27. doi: 10.1016/j.jacc.2013.03.034. Epub 2013 Apr 10. Erratum in: J Am Coll Cardiol. 2013 Aug 13;62(7):666.

4.

Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.

Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ.

J Vasc Interv Radiol. 2013 Feb;24(2):165-73; quiz 174. doi: 10.1016/j.jvir.2012.10.004. Epub 2013 Jan 28.

PMID:
23369553
5.

A meta-analysis of proximal occlusion device outcomes in carotid artery stenting.

Bersin RM, Stabile E, Ansel GM, Clair DG, Cremonesi A, Hopkins LN, Nikas D, Reimers B, Sievert H, Rubino P.

Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1072-8. doi: 10.1002/ccd.24433. Epub 2012 Jul 23.

PMID:
22454248
6.

Improved antiplatelet therapy? There's a generic thought.

Ansel GM.

Catheter Cardiovasc Interv. 2012 Mar 1;79(4):549. doi: 10.1002/ccd.24344. No abstract available.

PMID:
22344987
7.

Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.

Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27.

8.

Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis.

Laird JR, Tehrani F, Soukas P, Joye JD, Ansel GM, Rocha-Singh K.

Catheter Cardiovasc Interv. 2012 Feb 15;79(3):430-6. doi: 10.1002/ccd.23292. Epub 2011 Dec 8.

PMID:
21805607
9.

Neuroprotection during carotid artery stenting using the GORE flow reversal system: 30-day outcomes in the EMPiRE Clinical Study.

Clair DG, Hopkins LN, Mehta M, Kasirajan K, Schermerhorn M, Schönholz C, Kwolek CJ, Eskandari MK, Powell RJ, Ansel GM; EMPiRE Clinical Study Investigators.

Catheter Cardiovasc Interv. 2011 Feb 15;77(3):420-9. doi: 10.1002/ccd.22789. Epub 2010 Nov 3.

PMID:
20853365
10.

Protected carotid stenting in high-risk patients: results of the SpideRX arm of the carotid revascularization with ev3 arterial technology evolution trial.

Safian RD, Jaff MR, Bresnahan JF, Foster M, Bacharach JM, Yadav J, Joye J, Myla S, Kassab E, Mann JT, Ansel GM; CREATE SpideRX Trial Investigators.

J Interv Cardiol. 2010 Oct;23(5):491-8. doi: 10.1111/j.1540-8183.2010.00578.x.

PMID:
20624206
11.

Safety and effectiveness of the INVATEC MO.MA proximal cerebral protection device during carotid artery stenting: results from the ARMOUR pivotal trial.

Ansel GM, Hopkins LN, Jaff MR, Rubino P, Bacharach JM, Scheinert D, Myla S, Das T, Cremonesi A; Investigators for the ARMOUR Pivotal Trial.

Catheter Cardiovasc Interv. 2010 Jul 1;76(1):1-8. doi: 10.1002/ccd.22439.

PMID:
20222019
12.

Carotid artery stenting in high surgical risk patients using the FiberNet embolic protection system: the EPIC trial results.

Myla S, Bacharach JM, Ansel GM, Dippel EJ, McCormick DJ, Popma JJ.

Catheter Cardiovasc Interv. 2010 May 1;75(6):817-22. doi: 10.1002/ccd.22386.

PMID:
20201102
13.

Evolving modalities for femoropopliteal interventions.

Ansel GM, Lumsden AB.

J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II82-97. doi: 10.1583/08-2654.1. Review.

PMID:
19624076
14.

The "art" of medicine and the "smokescreen" of the randomized trial off-label use of vascular devices.

Ansel GM, Jaff MR.

Catheter Cardiovasc Interv. 2008 Dec 1;72(7):998-1002. doi: 10.1002/ccd.21776.

PMID:
19021289
15.
16.

Carotid stenting with embolic protection: evolutionary advances.

Ansel GM, Jaff MR.

Expert Rev Med Devices. 2008 Jul;5(4):427-36. doi: 10.1586/17434440.5.4.427. Review.

PMID:
18573043
17.

Long-term results of carotid stenting versus endarterectomy in high-risk patients.

Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE; SAPPHIRE Investigators.

N Engl J Med. 2008 Apr 10;358(15):1572-9. doi: 10.1056/NEJMoa0708028.

18.

Tibial intervention; no fear!

Ansel GM.

Catheter Cardiovasc Interv. 2007 Dec 1;70(7):1040. No abstract available.

PMID:
18044773
19.

Ground Hog Day.

Ansel GM.

Catheter Cardiovasc Interv. 2007 Jul 1;70(1):155. No abstract available.

PMID:
17585393
20.

Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease.

Ansel GM.

Catheter Cardiovasc Interv. 2007 May 1;69(6):886-9. No abstract available.

PMID:
17427903
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk